Placeholder

Global Uterine cancer therapeutics & Diagnostics Market – Segmented by type of cancer and geography (2015-2020)

Published by: | Published Date: January, 2016 | Number of pages: NA

$4,250$8,750

Clear
Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. According to the American Cancer Society, around 47,130 new cases of endometrial cancer were diagnosed, and 8,010 women died from it in 2012.

The Global Uterine Cancer Market is expected to grow modestly from USD 19,500 million in 2015, at a CAGR of 2-6%.

The global uterine cancer therapeutics & diagnostic market is segmented based on:

Type
Uterine sarcomas
Endometrial carcinomas (Has various sub-types)
Treatment
Surgery
Chemotherapy
Immunotherapy
Radiation therapy
Follow-up Treatment.
Furthermore, the diagnostics market is segmented under major tests such as:

Biopsy
Pelvic Ultrasound
Hysteroscopy
Dilation and curettage
CT Scan
Based on geography it is segmented as:

Asia-Pacific
North America
Europe
Latin America
According to the surveys by WHO, incidences of endometrial cancer is greater in the developed regions such as the North American countries followed by the European nations due to the shifting lifestyle of women. Pervasiveness of uterine cancer is more in women aged 50 years and above.

Some of the key participants in the industry include Ariad Pharmaceuticals, Inc., Abbott Laboratories, Becton, Dickinson & Co., Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Sanofi, Siemens Healthcare Inc., Roche Ltd etc.

Drivers:

Upsurge in awareness about uterine diseases
Available therapies in the market
Increasing health care expenditure
Increasing incidences of uterine cancer
Technological developments & drug innovations with regard to uterine cancer
Advanced health care services
Restraints:

Low success rate in clinical trials for cancer drugs
High cost associated with the treatment
Adverse side-effects
High toxicity of drugs
1. Introduction

1.1 Market Definition

1.2 Research Methodology

2. Executive Summary

3. Market Overview

3.1 Market Drivers

3.1.1 Rise in awareness about Uterine diseases and their available therapies

3.1.2 Increasing health care expenditure

3.1.3 Innovation in drug development, and subsequent technological advancements

3.2 Market Restraints

3.2.1 Low success rate in clinical trails for cancer drugs

3.2.2 High cost associated with the treatment

3.2.3 Adverse side-effects of treatment and high toxicity of drugs

3.3 Market Opportunitites

3.4 Market Threats

4. Porters Five Force Analysis

4.1 Bargaining Power of suppliers

4.2 Bargaining power of buyers

4.3 Degree of competition

4.4 Threat of substitution

4.5 Threat of new entrants

5. Market Segmentation

5.1 Global Uterine Cancer Therapeutics & Diagnostic Market, by Cancer Type

5.1.1 Uterine sarcomas

5.1.2 Endometrial carcinomas

5.1.2.1 Adenocarcinoma

5.1.2.2 Carcinosarcoma

5.1.2.3 Squamous cell carcinoma

5.1.2.4 Others

5.2 Global Uterine Cancer Therapeutics Market

5.2.1 Surgery

5.2.2 Immunotherapy

5.2.3 Radiation therapy

5.2.4 Chemotherapy

5.2.5 Follow-up Treatment

5.3 Global Uterine Cancer Diagnostics Market

5.3.1 Biopsy

5.3.2 Pelvic ultrasound.

5.3.3 Hysteroscopy

5.3.4 Dilation and curettage

5.3.5 CT scan

5.4 Global Uterine Cancer Therapeutics Market, By Region

5.4.1 North America

5.4.1.1 U.S.

5.4.1.2 Canada

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 France

5.4.2.3 Spain

5.4.2.4 Italy

5.4.2.5 U.K.

5.4.2.6 Rest Of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 India

5.4.3.3 Japan

5.4.4 Latin America

5.4.5 Middle East & Africa

6. Competitive Landscape

6.1 Mergers & Acquisitions

6.2 Agreements, Collaborations & Partnerships

6.3 New Product Launches

6.4 Recommendations to new market players

7. Company Profiles

7.1 Ariad Pharmaceuticals, Inc.

7.2 Abbott Laboratories

7.3 Becton, Dickinson & Co.

7.4 GlaxoSmithKline Plc

7.5 Merck & Co., Inc.

7.6 Novartis AG

7.7 Sanofi

7.8 Siemens Healthcare Inc

7.9 Roche Ltd

8. Appendix

8.1. Abbreviations

8.2. Sources

8.3. Bibliography

8.4. Disclaimer
Request Data
Request Data
Request Data